Focused On-demand Library for Adhesion G-protein coupled receptor G1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q9Y653

UPID:
AGRG1_HUMAN

ALTERNATIVE NAMES:
G-protein coupled receptor 56; Protein TM7XN1

ALTERNATIVE UPACC:
Q9Y653; A6NIT7; A6NJV9; B0M0K4; B4DR54; O95966; Q6ZMP1; Q8NGB3; Q96HB4

BACKGROUND:
The Adhesion G-protein coupled receptor G1, known alternatively as G-protein coupled receptor 56 or Protein TM7XN1, is integral to various physiological processes including cell adhesion, neuronal development, and hematopoietic stem cell maintenance. It binds to collagen III/COL3A1, regulating cortical development and neuronal migration. Additionally, it plays a role in cancer progression by modulating VEGFA production and angiogenesis, as well as being essential in testis development.

THERAPEUTIC SIGNIFICANCE:
The involvement of Adhesion G-protein coupled receptor G1 in polymicrogyria, a cortical malformation disorder, underscores its potential as a therapeutic target. The protein's role in cancer progression and angiogenesis further highlights its significance in developing treatments for cancer and neurological conditions. Exploring Adhesion G-protein coupled receptor G1's functions could lead to groundbreaking therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 400 of 8789